Chris Martin | [email protected] | 630.670.2745
DENVER – The International Association for the Study of Lung Cancer (IASLC) today reported that its main cancer journal, the Journal of Thoracic Oncology, improved its Impact Factor from 13.357 in 2019 to 15.609 in 2020. The JTO, the official journal of the IASLC, now ranks 13th out of all 242 oncology journals and 4th out of all 64 respiratory system journals.
Impact Factors are measured by calculating the number of times journal articles in the two preceding years are cited in a current year. Thus, the Impact Factor for 2020 is the number of times articles published in 2018 and 2019 are cited in 2020. The higher the Impact Factor, the more highly ranked the journal. Journal citation reports are issued by Clarivate Analytics.
The JTO is the primary educational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Emphasizing a multidisciplinary approach, the JTO includes original research, review articles and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists and basic scientists with a special interest in thoracic oncology.
“It is generally difficult for organ specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 15.609, JTO is the leading journal in thoracic oncology and in the top fifteen (ranked 13th) of all cancer journals, ” said Editor-in-Chief, Alex A. Adjei, M.D. “JTO’s emphasis on multidisciplinary research is one of its strengths and serves the broad community of researchers in this field.”
The JTO continues to have a quick turn-around time of 5.3 days to initial decision, and an average of 9 days for revisions, a fast-track category, publish on acceptance (within 5 days) and promotion of select articles via social media and press releases. In 2020, IASLC also launched an open access journal, JTO Clinical and Research Reports, to expand their ability to publish quality research in thoracic oncology. Authors can promote their own research by utilizing Elsevier enhancements such as Sharelink.
To submit a manuscript or to learn more about the JTO, please visit jto.org. Once there, readers can peruse current in-press articles, collections of lung cancer staging and pathology articles and the freely available Editor’s Choice articles. The full contents of the JTO are a free benefit for IASLC members.